Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Langue: | |
| Publié: |
Zenodo
2025
|
| Accès en ligne: | https://doi.org/10.5281/zenodo.14874332 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Table des matières:
- <p>Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by impaired social <br>interaction, communication difficulties, and repetitive behaviours. Emerging evidence suggests that serotonin (5-<br>hydroxytryptamine, 5-HT) plays a pivotal role in ASD pathophysiology. Serotonin's widespread influence on <br>neurodevelopmental processes, including neurogenesis, synaptogenesis, and neural circuit formation, underscores its <br>significance in ASD research. Hyperserotonemia, a condition marked by elevated blood serotonin levels, has been <br>identified as the first biomarker of ASD, affecting approximately 30% of individuals with the disorder. Genetic studies <br>implicate serotonin transporter (SERT) gene variations, such as the Ala56 variant, in ASD-associated behavioural<br>abnormalities. Functional imaging and biochemical studies reveal disruptions in serotonin synthesis, receptor binding, <br>and transporter activity in autistic individuals.</p>